SMAD3

Across TCGA pan-cancer cohorts, SMAD3 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated SMAD3 data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher SMAD3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SMAD3 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

KICH, LUAD, and LGG are the cancer types where SMAD3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
LUAD	OS	Median	All	0.307	0.834	.001	9	view →
LGG	DFS	Median	All	0.275	0.753	.041	6	view →
BRCA	DFS	Median	All	0.112	0.525	.031	6	view →
LUSC	DFS	Median	All	0.064	0.791	<.001	5	view →
SKCM	DFS	Median	All	0.130	0.728	.003	4	view →
COAD	OS	Median	III,IV	0.491	0.796	.033	3	view →
BLCA	DFS	Median	III,IV	0.835	0.264	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

SMAD3–KICH (DFS)

Open the KICH breakdown →